Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

Fig. 5

a: CEA/CEACAM5 mRNA expression in sorted CEAhi/lo cells. A paired Student’s t-test was applied to log2 transformed gene expression data for significance analysis. b: Significant results of the gene set enrichment analysis of sorted CEAhi and CEAlo cells from CRC-03, CRC-08 and CRC-06. WNT/β-catenin and oxidative phosphorylation signatures were significantly enriched in cells expressing low CEA levels. c: mRNA expression heatmaps generated by GSEA showing expression levels of genes in the significantly enriched pathways. d: Representation of the APC gene and of the specific protein changes encoded by APC mutations found in 7/8 PDOs. e: Expression of genes which have been described as CRC stem cell markers in sorted CEAhi/lo cells. f: CEA expression analysis of PDOs treated for 4 days with DMSO control (grey), with a 10uM of porcupine inhibitor (blue) or 10uM of a Tankyrase inhibitor

Back to article page